Atreca Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
May 13 2020 - 5:00PM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
that a trial in progress poster will be presented at the American
Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
being held from May 29 to May 31, 2020. The poster will describe
the design of the company’s ongoing Phase 1b first-in-human
clinical trial evaluating ATRC-101 in patients with select solid
tumor cancers.
Details of Atreca’s poster presentation:
Abstract Title: First-in-human Phase 1b study of ATRC-101, an
engineered version of a patient-derived antibody targeting a
tumor-restricted ribonucleoprotein complex.
Session Title: Developmental Therapeutics – Immunotherapy
The abstract can be found on the ASCO website and the poster
will be made available on the company’s website once the virtual
program begins on Friday, May 29 at 8:00 a.m. EDT.
About ATRC-101ATRC-101 is a monoclonal antibody
derived from an antibody identified using Atreca’s discovery
platform. ATRC-101 is believed to function through Driver Antigen
Engagement, a novel mechanism of action in oncology. This mechanism
involves systemic delivery of an antibody that has been shown in
preclinical models to engage the innate immune system, cause
remodeling of the tumor microenvironment and drive T cell-mediated
destruction of tumor cells. Atreca has identified the target of
ATRC-101 as a ribonucleoprotein (RNP) complex. Underlining the
rationale for human testing, ATRC-101 has demonstrated robust
anti-tumor activity as a single agent in multiple preclinical
syngeneic tumor models, including one model in which PD-1
checkpoint inhibitors typically display limited activity. Further,
ATRC-101 has been shown to react in vitro with a majority of human
ovarian, non-small cell lung, colorectal, breast cancers and acral
melanoma samples from multiple patients.
About Atreca, Inc. Atreca is a
biopharmaceutical company developing novel antibody-based cancer
immunotherapeutics generated by its differentiated discovery
platform. Atreca’s platform allows access to an unexplored
landscape in oncology through the identification of unique
antibody-target pairs generated by the human immune system during
an active immune response against tumor. These antibodies provide
the basis for first-in-class therapeutic candidates, such as lead
product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in
multiple solid tumor cancers is currently enrolling patients. For
more information on Atreca, please visit www.atreca.com.
Forward-Looking StatementsThis release contains
forward-looking statements regarding our strategy and future plans,
including statements regarding the development of ATRC-101 and our
clinical and regulatory plans, and the timing thereof. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as “will”, “believe,” and similar
words, although some forward-looking statements are expressed
differently. Our actual results may differ materially from those
indicated in these forward-looking statements due to risks and
uncertainties related to the initiation, timing, progress and
results of our research and development programs, preclinical
studies, any clinical trials and Investigational New Drug
application and other regulatory submissions, and other matters
that are described in our Annual Report on Form 10-K for the fiscal
year ended December 31, 2019 filed with the Securities and Exchange
Commission (SEC) and available on the SEC’s website at www.sec.gov,
including the risk factors set forth therein. Investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release, and we
undertake no obligation to update any forward-looking statement in
this press release, except as required by law.
ContactsAtreca, Inc. Herb Cross Chief Financial
Officer info@atreca.com
Investors: Alex Gray, 650-779-9251 agray@atreca.com
Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.comSource:
Atreca, Inc.
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Oct 2023 to Oct 2024